INDIANAPOLIS, Nov. 1, 2021 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will participate in Bernstein's Second Annual
Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van Naarden,
CEO of Loxo Oncology at Lilly and president of Lilly Oncology;
Mark Mintun, senior vice president,
research and development – neuroscience, and president, Avid
Radiopharmaceuticals; and Jamie
Croaning, global development leader – tirzepatide, will
participate in a virtual fireside chat at 12:30 p.m., Eastern time.
A live audio webcast will be available on the "Webcasts &
Presentations" section of Lilly's Investor website at
https://investor.lilly.com/webcasts-and-presentations. A replay of
the presentation will be available on this same website for
approximately 90 days.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with
discovery to create medicines that make life better for people
around the world. We were founded more than a century ago by a man
committed to creating high-quality medicines that meet real needs,
and today we remain true to that mission in all our work. Across
the globe, Lilly employees work to discover and bring life-changing
medicines to those who need them, improve the understanding and
management of disease, and give back to communities through
philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and www.lilly.com/news. F-LLY
Refer
to:
|
Jordan
Bishop; bishop_jordan@lilly.com; 317-473-5712
(Media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; 317-277-1838
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-bernsteins-second-annual-operational-decisions-conference-301412916.html
SOURCE Eli Lilly and Company